Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 13, 2021

Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-?, BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 27, 2019

If you thought there was no relationship between cannabis use and technology, consider these stats: the average number of mobile apps being used in a day by current cannabis users are 4. Virtual Clinical Trials transcend geographic, mobility and economic barriers. Authored By : Arundati Dandapani.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 10, 2022

Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. It’s clear that alternative treatment options are necessary to combat depression and other mental illnesses, which is where companies developing psychedelic-based treatments like Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Canna Law Blog

NOVEMBER 15, 2021

There was a fascinating panel on the use of ketamine treatments for, among other things, depression and anxiety disorders. We continue to see an uptick in ketamine clinic transactions (the complexities of which we have written about extensively ). Pharmaceutical start-ups are betting on the treatment potential of psychedelics.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

AUGUST 9, 2021

Investors will continue to keep an eye on several ongoing clinical trials, as well as private companies that are gearing up to go public over the coming quarters. NEO: MEDI) (OTC: KONEF) signed an exclusive agreement for the use of VR technology in psychedelic treatments with OVR Tech LLC. via Business Insider.

Clinical Trials 105

Clinical Trials Decriminalization Research and Development Treatment 105

Cannabis Law Report

AUGUST 2, 2021

capital markets, negative global economic conditions, potential negative developments in our clinical trials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co.,

Clinical Trials 105

Clinical Trials Research and Development Treatment Conditions 105

Veriheal

MAY 25, 2023

What was once used as an ideal anesthetic for monkeys could soon be competing with cannabis as a medical aid. Currently, the only ketamine treatment for depression that insurance will cover is esketamine (Spravato) , an FDA-approved nasal spray. In Manhattan alone, 12 clinics have already opened their doors. million by 2027.

Medicine 89

Medicine Blood Pressure Therapy Clinical Trials 89

Cannabis Law Report

JULY 27, 2021

–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., The ORR is a web-based research platform open to adults and adult caregivers of dependents who are, or are considering, the use of cannabis or hemp products for therapeutic purposes.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

JUNE 30, 2021

LONDON–(BUSINESS WIRE)– Fourfive , the CBD and nutrition brand loved by athletes and those leading an active lifestyle, today called on the UK’s sports governing bodies to stop sitting if on the fence and conduct clinical trials into the effectiveness of CBD and medicinal cannabis in professional sport.

Medicine 75

Medicine Clinical Trials CBD Sleep 75

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

AUGUST 3, 2021

TORONTO–( BUSINESS WIRE )– Cybin Inc. Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. The Neo Exchange Inc.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JANUARY 12, 2022

OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. 14, 2021, the sale of Gb Sciences’ Las Vegas cannabis facility was finalized on Dec. LAS VEGAS, Jan.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

JUNE 24, 2022

The legislation from Senate President Nicholas Scutari (D), who has long championed cannabis reform in the Garden State, would further create a system of licensed businesses to provide psilocybin services in supervised settings. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Info

OCTOBER 11, 2019

European Cannabis Business News and Updates for This Week. 10 Dutch Municipalities Will Have Authorized Recreational Cannabis For The First Time. Germany’s ExpoPharm Features Cannabis For The First Time. MediPharm Labs, a Canadian cannabis agency, can be set to supply products for 20,000 pharmacies in Germany.

Business 45

Business Epilepsy Clinical Trials Treatment 45

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up. at the end of the 17 weeks of ganaxolone treatment. ET (12:00 p.m.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JANUARY 10, 2022

DUBLIN–(BUSINESS WIRE)–The “U.S. In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. Cannabis and Cannabinoids Regulatory Framework in U.S. Market Outlook.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global medical cannabis market exhibited strong growth during 2015-2020. Aurora Cannabis Inc.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

Cannabis Law Report

SEPTEMBER 1, 2021

The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). CAMBRIDGE, Mass.–(BUSINESS Stern Investor Relations, Inc. 212-362-1200.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Bilmoria opine: “[R]emoving cannabis from Schedule I of the CSA would mean that it could be treated as any other physician-prescribed drug. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

AUGUST 17, 2021

DUBLIN–(BUSINESS WIRE)–The “Respiratory Health Management Technology Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Most of the Mobile Medical Applications in Clinical Trials are Monitoring Symptoms that can Support Early Disease Diagnosis. Research Scope.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

Cannabis Law Report

JANUARY 19, 2022

–(BUSINESS WIRE)– #IGC –India Globalization Capital, Inc. He understands that treatment and education for conditions such as Autism and Alzheimer’s disease have the potential to positively impact millions of lives. The Company also operates an infrastructure business based in India. POTOMAC, Md.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52